0001636282-25-000063.txt : 20250602 0001636282-25-000063.hdr.sgml : 20250602 20250602160210 ACCESSION NUMBER: 0001636282-25-000063 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250529 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250602 DATE AS OF CHANGE: 20250602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 251014831 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 8-K 1 syre-20250529.htm 8-K syre-20250529
false000163628200016362822025-05-292025-05-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________

FORM 8-K
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2025
_______________________________________________________
SPYRE THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
_______________________________________________________
Delaware001-3772246-4312787
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
221 Crescent Street
Building 23
Suite 105
 
Waltham, MA
 
02453
(Address of Principal Executive Offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code: 617 651-5940
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per Share
SYRE
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.07    Submission of Matters to a Vote of Security Holders.
On May 29, 2025, Spyre Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The proposals considered at the Annual Meeting are described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 14, 2025. The final voting results were as follows:
Proposal No. 1
The Company’s stockholders elected three Class III directors, Peter Harwin, Michael Henderson, and Sandra Milligan, each to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
NomineesForWithheldBroker Non-Votes
Peter Harwin38,196,0607,977,3233,120,432
Michael Henderson, M.D.
45,441,918731,4653,120,432
Sandra Milligan, M.D., J.D.
37,612,7958,560,5883,120,432
Proposal No. 2
The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers.
ForAgainstAbstainBroker Non-Votes
42,930,7203,144,04098,6233,120,432
Proposal No. 3
The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025.
ForAgainstAbstainBroker Non-Votes
49,227,86357,1238,8290



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  
SPYRE THERAPEUTICS, INC.
   
Date:
June 2, 2025
By:
/s/ Cameron Turtle
   
Cameron Turtle
Chief Executive Officer

 EX-101.SCH 2 syre-20250529.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 syre-20250529_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Registrant Name Entity Registrant Name EX-101.PRE 4 syre-20250529_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover Page
May 29, 2025
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name SPYRE THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37722
Entity Tax Identification Number 46-4312787
Entity Address, Address Line One 221 Crescent Street
Entity Address, Address Line Two Building 23
Entity Address, Address Line Three Suite 105
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02453
City Area Code 617
Local Phone Number 651-5940
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 Par Value Per Share
Trading Symbol SYRE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001636282
Document Period End Date May 29, 2025
XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://spyre.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports syre-20250529.htm syre-20250529.xsd syre-20250529_lab.xml syre-20250529_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "syre-20250529.htm": { "nsprefix": "syre", "nsuri": "http://spyre.com/20250529", "dts": { "inline": { "local": [ "syre-20250529.htm" ] }, "schema": { "local": [ "syre-20250529.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "syre-20250529_lab.xml" ] }, "presentationLink": { "local": [ "syre-20250529_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://spyre.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "syre-20250529.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "syre-20250529.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Three", "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://spyre.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0001636282-25-000063-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001636282-25-000063-xbrl.zip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end XML 14 syre-20250529_htm.xml IDEA: XBRL DOCUMENT 0001636282 2025-05-29 2025-05-29 false 0001636282 8-K 2025-05-29 SPYRE THERAPEUTICS, INC. DE 001-37722 46-4312787 221 Crescent Street Building 23 Suite 105 Waltham MA 02453 617 651-5940 false false false false Common Stock, $0.0001 Par Value Per Share SYRE NASDAQ false